Hikma Pharmaceuticals PLC (OTCMKTS:HKMPF – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2026 EPS estimates for shares of Hikma Pharmaceuticals in a report released on Friday, May 20th. Jefferies Financial Group analyst J. Vane-Tempest forecasts that the company will post earnings per share of $2.37 for the year.
Other equities research analysts also recently issued research reports about the company. Morgan Stanley reduced their target price on Hikma Pharmaceuticals from GBX 2,300 ($28.35) to GBX 2,100 ($25.89) in a research report on Friday, May 6th. JPMorgan Chase & Co. decreased their target price on shares of Hikma Pharmaceuticals from GBX 3,000 ($36.98) to GBX 2,900 ($35.75) in a research report on Wednesday, March 2nd. Finally, Zacks Investment Research lowered shares of Hikma Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $1,677.00.
Hikma Pharmaceuticals Company Profile (Get Rating)
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded.
- Get a free copy of the StockNews.com research report on Hikma Pharmaceuticals (HKMPF)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.